Gland Pharma LtdNSE:GLAND
Current view Q4 2026
Injectable-drug maker whose loss-making Europe unit finally turned profitable, powering profit up 47%. Contract manufacturing is the growth engine, plus future weight-loss-drug upside. But that Europe fix arrived a year late.
Latest exchange filings last 5 · 5 after Q4 2026
- 13 Sep ’26Board approved acquiring Gland Pharma USA Inc. for USD 501,208; direct subsidiary by October 31, 2026. ↗
- 13 Sep ’26Board approved USD 501,208 acquisition of Gland Pharma USA Inc; completion expected by October 31, 2026. ↗
- 13 Sep ’26Allotment of 44,193 Equity Shares on exercise of ESOPs ↗
- 13 Sep ’26Gland Pharma granted 5,90,249 stock options to 124 employees under ESOP 2025 on September 13, 2026. ↗
- 13 Sep ’26Board noted ₹70,000 fine each from NSE and BSE for July 18 director compliance lapse; paid in full. ↗
Exchange filings, with the company's own one-line summary, read off the same page as the figures. Screener publishes only the most recent few, so this is the last 5 — not everything filed since your note, and a quiet-looking list is not proof of a quiet quarter. A filing is marked new when it is dated after the end of the quarter your note covers. Not scored, and not a judgement — a routine repayment notice and a takeover sit in the same list.
AI concall report · Q4 2026
The full earnings-call read behind this view — what management promised, what they delivered, and the earning trigger.
Growth Q4 2026
| Metric | This year vs lastYoY · vs Q4 2025 | vs the quarter beforeQoQ, sequential · vs Q3 2026 | 3-year yearly average3Y CAGR · compounded | 5-year yearly average5Y CAGR · compounded |
|---|---|---|---|---|
| Sales | ▲ +22.3% | +2.8% | +21.1% | +13.2% |
| Operating profit | ▲ +47.4% | +17.9% | +16.7% | +6.0% |
| EPS | ▲ +96.6% | +40.3% | +9.6% | +0.5% |
| PAT | ▲ +96.3% | +40.6% | — | — |
Tinted rows drive the Tier. Tier = the weaker of YoY Sales and YoY PAT growth. Here the weaker is Sales at +22.3%, which is ≥ 20% → Tier 1.
QoQ is sequential, not a trend. For most Indian companies the March quarter is seasonally the largest, so a June-quarter fall against it is a calendar effect. Only the YoY column feeds the Tier.
Multibagger potential
Average59/100
Growing, but too slowly to re-price. Profit per share grew 10% a year. A big re-pricing usually needs more than 15% a year, so the score is capped no matter how cheap it looks.
₹2,896 → ₹5,792 needs the P/E at 71× — it is 46× today, and has ranged 19× to 62× over the last 5 years. The rest would come from earnings growing as they have.
What you pay for its profitlog scale · 5-year range
Tripling needs 106× — never traded above 62× in 5 years.
Re-rated already, on growth that doesn't fully back it.
How this is calculated
This is arithmetic, not a forecast — Return = ΔEPS × ΔMultiple. It says what would have to be true, not how likely it is, and "earnings keep growing at this rate for three more years" is the assumption doing the most work. This is a large-cap at ₹46,886 cr, so the odds of a re-rate are not fighting its own size.
Band capped: growth of 9.6% is below the 15% bar a re-rate needs.
Growth rate used: 9.6% — the weakest of EPS / Sales / Op-profit from 3-year EPS CAGR. Latest quarter reads 60%.
How it compares with its rivals Healthcare · 6 of 159 listed
It earns 15% on its capital, sixth of 6, and it is the third most expensive of the 6 shown.
| Company | Price | P/E | Size | ROCE | Profitlast qtr | Saleslast qtr |
|---|---|---|---|---|---|---|
| Gland Pharma | ₹2,950 | 42.6× | ₹48,677 Cr | 15.1% | +47.1% | +19.6% |
| Sun Pharma.Inds. | ₹1,853 | 35.1× | ₹4.45 L Cr | 20.5% | +6.0% | +10.5% |
| Divi's Lab. | ₹9,376 | 83.5× | ₹2.49 L Cr | 22.0% | +65.5% | +27.8% |
| Torrent Pharma. | ₹4,855 | 82.8× | ₹1.85 L Cr | 15.2% | +5.8% | +54.9% |
| Zydus Lifesci. | ₹1,155 | 23.7× | ₹1.15 L Cr | 21.1% | −35.1% | +22.0% |
| Cipla | ₹1,375 | 31.0× | ₹1.11 L Cr | 15.5% | −39.2% | +2.3% |
Screener's own peer group, from the request already made for the industry P/E. It serves the industry's largest names by market cap, not companies of a similar size, so treat this as context rather than a like-for-like table; this company is always shown. On a phone the price, size and sales columns are dropped rather than pushed off the edge. Not part of the score.
Business quality to Jun 2026
| Are the margins widening? | yes — a little wider than 3 years earlier | operating margin 24% → 27% over 3 years |
|---|---|---|
| Did the profit turn into cash? | most of it arrived as cash | 91% last year, 96% over three · free cash flow ₹538 cr, positive in 5 of 5 years |
| Is the growth borrowed? | essentially debt-free | ₹284 cr — 0.03× its own equity (was 0.03×) |
| Is it being collected? | collection is steady | 107 days to collect, up 8 in a year · cash cycle 255 days |
| Who has been buying? | the promoters have held steady | promoters 51.8% (−0.1 in a year), 57.9% → 51.8% over 2.8 years · FIIs 8.7% (+1.4) · DIIs 30.4% (−2.4) · shareholders 1,61,627 → 1,08,266 |
| What does it earn on its capital? | earns a fair return on its capital | ROCE 15.1% · ROE 10.7% |
Fetched from the filings, not typed — and deliberately not part of the score. These are the questions the score cannot ask: it reads growth, price and trend, so a company can score well while its profit never becomes cash. Weigh these beside the note, not against the number.
Screener's own checklist not mine, not the score
In its favour
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 39.1%
Against it
- Stock is trading at 4.68 times its book value
- Company has a low return on equity of 9.29% over last 3 years.
- Promoter holding has decreased over last 3 years: -6.09%
Generated by screener.in from a fixed checklist — not written by me and not an input to the score. It is here as a second machine opinion to weigh against the note; where it disagrees with the view above, the note is the considered one.